» Articles » PMID: 31541276

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2019 Sep 22
PMID 31541276
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In patients with idiopathic pulmonary fibrosis (IPF), hospitalizations are associated with high mortality. We sought to determine in-hospital mortality rates and factors associated with in-hospital mortality in patients with IPF.

Methods: Patients with IPF were identified from the Premier Healthcare Database, a representative administrative dataset that includes > 20% of hospital discharges in the US, using an algorithm based on diagnostic codes and billing data. We used logistic regression to analyze associations between patient-, hospital-, and treatment-related characteristics and a composite primary outcome of death during the index visit, lung transplant during the index visit and > 1 day after admission, or death during a readmission within 90 days.

Results: The cohort comprised 6665 patients with IPF hospitalized between October 2011 and October 2014. A total of 963 (14.4%) met the primary outcome. Factors significantly associated with a higher risk of the primary outcome included mechanical ventilation [odds ratio 4.65 (95% CI 3.73, 5.80)], admission to the intensive care unit [1.83 (1.52, 2.21)], treatment with opioids (3.06 [2.57, 3.65]), and a diagnosis of pneumonia [1.44 (1.21, 1.71)]. Factors significantly associated with a lower risk included concurrent chronic obstructive pulmonary disease [0.65 (0.55, 0.77)] and female sex [0.67 (0.57, 0.79)].

Conclusions: Patients with IPF, particularly those receiving mechanical ventilation or intensive care, are at substantial risk of death or lung transplant during hospitalization or death during a readmission within 90 days.

Citing Articles

Successful resection of bilateral parafalcine meningioma with unilateral interhemispheric and contralateral transfalcine approach under nonintubated spontaneous breathing conditions: illustrative case.

Hirono S, Kawano K, Ito M, Saito K, Hayashida T, Higuchi Y J Neurosurg Case Lessons. 2024; 7(15).

PMID: 38588594 PMC: 11007272. DOI: 10.3171/CASE2424.


The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Baig S, Yoo E Life (Basel). 2024; 14(1).

PMID: 38276285 PMC: 10817308. DOI: 10.3390/life14010156.


Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.

Lee H, Jung S, Jang J, Ko J, Kim D, Her M Life (Basel). 2023; 13(11).

PMID: 38004258 PMC: 10672649. DOI: 10.3390/life13112118.


Integrated bioinformatics analysis for the identification of idiopathic pulmonary fibrosis-related genes and potential therapeutic drugs.

Zhang Z, Guan Q, Tian Y, Shao X, Zhao P, Huang L BMC Pulm Med. 2023; 23(1):373.

PMID: 37794454 PMC: 10552267. DOI: 10.1186/s12890-023-02678-z.


Hospital-level variation in practices and outcomes for patients with severe acute exacerbations of idiopathic pulmonary fibrosis: a retrospective multicentre cohort study.

Shankar D, Walkey A, Hawkins F, Bosch N, Peterson D, Law A BMJ Open Respir Res. 2023; 10(1).

PMID: 37076251 PMC: 10124258. DOI: 10.1136/bmjresp-2022-001593.


References
1.
Pedraza-Serrano F, Lopez de Andres A, Jimenez-Garcia R, Jimenez-Trujillo I, Hernandez-Barrera V, Sanchez-Munoz G . Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004-2013) using administrative data. BMJ Open. 2017; 7(2):e013156. PMC: 5318548. DOI: 10.1136/bmjopen-2016-013156. View

2.
Collard H, Chen S, Yeh W, Li Q, Lee Y, Wang A . Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015; 12(7):981-7. DOI: 10.1513/AnnalsATS.201412-553OC. View

3.
Noble P, Albera C, Bradford W, Costabel U, du Bois R, Fagan E . Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2015; 47(1):243-53. PMC: 4697914. DOI: 10.1183/13993003.00026-2015. View

4.
Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L . Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019; 6(1):e000397. PMC: 6530503. DOI: 10.1136/bmjresp-2018-000397. View

5.
Durheim M, Collard H, Roberts R, Brown K, Flaherty K, King Jr T . Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015; 3(5):388-96. PMC: 4760351. DOI: 10.1016/S2213-2600(15)00093-4. View